[c-MET Oncogene in Renal Cell Carcinomas].
[c-MET Oncogene in Renal Cell Carcinomas].
Aktuelle Urol. 2016 Dec;47(6):475-479
Authors: Erlmeier F, Weichert W, Autenrieth M, Ivanyi P, Hartmann A, Steffens S
Abstract
c-Met plays a significant role in multiple cellular processes. Being encoded by a proto-oncogene, tyrosine kinase supports aggressive tumour behaviour such as tumour invasiveness and formation of metastases. For some subtypes of renal cell carcinoma studies have shown a association between c-Met expression and clinical outcome or prognosis. Therefore, c-Met represents a prognostic marker in renal cell carcinoma.Furthermore, c-MET will play a decisive role as a possible target for targeted therapies in the era of personalised medicine. Especially for RCC, the dual inhibition of VEGF and c-MET tyrosine kinase in cases of metastatic, treatment-resistant tumours is gaining clinical relevance. The role of c-Met has not been fully elucidated for all subtypes of renal cell carcinomas. The relevance of c-Met for the remaining subtypes of renal tumours has yet to be clarified.
PMID: 28006830 [PubMed - in process]
Source: Aktuelle Urologie - Category: Urology & Nephrology Authors: Erlmeier F, Weichert W, Autenrieth M, Ivanyi P, Hartmann A, Steffens S Tags: Aktuelle Urol Source Type: research
More News: Cancer & Oncology | Carcinoma | Kidney Cancer | Renal Cell Carcinoma | Study | Urology & Nephrology